The Experts below are selected from a list of 55176 Experts worldwide ranked by ideXlab platform
Satish S C Rao - One of the best experts on this subject based on the ideXlab platform.
-
dysmotility and Proton Pump Inhibitor use are independent risk factors for small intestinal bacterial and or fungal overgrowth
Alimentary Pharmacology & Therapeutics, 2013Co-Authors: Carolyn Jacobs, Coss E Adame, Ashok Attaluri, Jessica Valestin, Satish S C RaoAbstract:Introduction Whether intestinal dysmotility and Proton Pump Inhibitor (PPI) use either independently or together contributes to small intestinal bacterial overgrowth (SIBO), and/or small intestinal fungal overgrowth (SIFO) is not known.
Chie Tamai - One of the best experts on this subject based on the ideXlab platform.
-
effect of a Proton Pump Inhibitor or an h2 receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer a prospective randomized controlled trial
The American Journal of Gastroenterology, 2007Co-Authors: Noriya Uedo, Yoji Takeuchi, Takuya Yamada, Ryu Ishihara, Hideharu Ogiyama, Sachiko Yamamoto, Motohiko Kato, Koichi Tatsumi, Eriko Masuda, Chie TamaiAbstract:Effect of a Proton Pump Inhibitor or an H 2 -Receptor Antagonist on Prevention of Bleeding From Ulcer After Endoscopic Submucosal Dissection of Early Gastric Cancer: A Prospective Randomized Controlled Trial
-
effect of a Proton Pump Inhibitor or an h2 receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer a prospective randomized controlled trial
The American Journal of Gastroenterology, 2007Co-Authors: Noriya Uedo, Yoji Takeuchi, Takuya Yamada, Ryu Ishihara, Hideharu Ogiyama, Sachiko Yamamoto, Motohiko Kato, Koichi Tatsumi, Eriko Masuda, Chie TamaiAbstract:Effect of a Proton Pump Inhibitor or an H 2 -Receptor Antagonist on Prevention of Bleeding From Ulcer After Endoscopic Submucosal Dissection of Early Gastric Cancer: A Prospective Randomized Controlled Trial
Colin W Howden - One of the best experts on this subject based on the ideXlab platform.
-
response of regurgitation to Proton Pump Inhibitor therapy in clinical trials of gastroesophageal reflux disease
The American Journal of Gastroenterology, 2011Co-Authors: Peter J Kahrilas, Colin W Howden, Nesta HughesAbstract:Response of Regurgitation to Proton Pump Inhibitor Therapy in Clinical Trials of Gastroesophageal Reflux Disease
-
Proton Pump Inhibitor therapy for suspected gerd related chronic laryngitis a meta analysis of randomized controlled trials
The American Journal of Gastroenterology, 2006Co-Authors: Mohammed A Qadeer, Pieter J Noordzij, Christopher O Phillips, Rocio A Lopez, David L Steward, Maria V Suurna, Thomas Havas, Colin W Howden, Michael F VaeziAbstract:Proton Pump Inhibitor Therapy for Suspected GERD-Related Chronic Laryngitis: A Meta-Analysis of Randomized Controlled Trials
-
systematic review and meta analysis enhanced efficacy of Proton Pump Inhibitor therapy for peptic ulcer bleeding in asia a post hoc analysis from the cochrane collaboration
Alimentary Pharmacology & Therapeutics, 2005Co-Authors: Grigoris I Leontiadis, Virender K Sharma, Colin W HowdenAbstract:Summary Background : Proton-Pump Inhibitors reduce re-bleeding rates after ulcer bleeding. However, there is significant heterogeneity among different randomized-controlled trials. Aim : To see whether Proton-Pump Inhibitors for ulcer bleeding produced different clinical outcomes in different geographical locations. Methods : This was a post hoc analysis of our Cochrane Collaboration systematic review and meta-analysis of Proton-Pump Inhibitor therapy for ulcer bleeding. Sixteen randomized-controlled trials conducted in Europe and North America were pooled and re-analysed separately from seven conducted in Asia. We calculated pooled rates for 30-day all-cause mortality, re-bleeding and surgical intervention and derived odds ratios and numbers needed to treat with 95% confidence intervals. Results : There was no significant heterogeneity for any outcome. Reduced all-cause mortality was seen in the Asian randomized-controlled trials (odds ratios = 0.35; 95% confidence interval: 0.16–0.74; number needed to treat = 33), but not in the others (odds ratios = 1.36; 95% confidence interval: 0.94–1.96; number needed to treat – incalculable). There were significant reductions in re-bleeding and surgery in both sets of randomized-controlled trials, but the effects were quantitatively greater in Asia. Conclusions : Proton-Pump Inhibitor therapy for ulcer bleeding has been more efficacious in Asia than elsewhere. This may be because of an enhanced pharmacodynamic effect of Proton-Pump Inhibitors in Asian patients.
-
systematic review and meta analysis of Proton Pump Inhibitor therapy in peptic ulcer bleeding
BMJ, 2005Co-Authors: Grigoris I Leontiadis, Virender K Sharma, Colin W HowdenAbstract:Objectives To review randomised controlled trials of treatment with a Proton Pump Inhibitor in patients with ulcer bleeding and determine the impact on mortality, rebleeding, and surgical intervention. Design Systematic review and meta-analysis. Data sources Cochrane Collaboration's trials register, Medline, and Embase, handsearched abstracts, and pharmaceutical companies. Review methods Included randomised controlled trials compared Proton Pump Inhibitor with placebo or H2 receptor antagonist in endoscopically proved bleeding ulcer and reported at least one of mortality, rebleeding, or surgical intervention. Trials were graded for methodological quality. Two assessors independently reviewed each trial, and disagreements were resolved by consensus. Results We included 21 randomised controlled trials comprising 2915 patients. Proton Pump Inhibitor treatment had no significant effect on mortality (odds ratio 1.11, 95% confidence interval 0.79 to 1.57; number needed to treat (NNT) incalculable) but reduced rebleeding (0.46, 0.33 to 0.64; NNT 12) and surgery (0.59, 0.46 to 0.76; NNT 20). Results were similar when the meta-analysis was restricted to the 10 trials with the highest methodological quality: 0.96, 0.46 to 2.01, for mortality; 0.41, 0.25 to 0.68, NNT 10, for rebleeding; 0.62, 0.46 to 0.83, NNT 25, for surgery. Conclusions Treatment with a Proton Pump Inhibitor reduces the risk of rebleeding and the requirement for surgery after ulcer bleeding but has no benefit on overall mortality.
Nesta Hughes - One of the best experts on this subject based on the ideXlab platform.
-
response of regurgitation to Proton Pump Inhibitor therapy in clinical trials of gastroesophageal reflux disease
The American Journal of Gastroenterology, 2011Co-Authors: Peter J Kahrilas, Colin W Howden, Nesta HughesAbstract:Response of Regurgitation to Proton Pump Inhibitor Therapy in Clinical Trials of Gastroesophageal Reflux Disease
Hashem B Elserag - One of the best experts on this subject based on the ideXlab platform.
-
systematic review persistent reflux symptoms on Proton Pump Inhibitor therapy in primary care and community studies
Alimentary Pharmacology & Therapeutics, 2010Co-Authors: Hashem B Elserag, A Becher, Roger JonesAbstract:Summary Background Persistent gastro-oesophageal reflux disease (GERD) symptoms can occur despite Proton Pump Inhibitor (PPI) therapy. Aim To assess the prevalence and potential determinants of persistent GERD symptoms in primary care and community-based studies. Methods Studies were identified by systematic PubMed and Embase searches; pooled prevalence data are shown as sample-size weighted means and 95% confidence intervals. Results Nineteen studies in individuals with GERD taking a PPI were included. In interventional, nonrandomized primary care trials, the prevalence of persistent troublesome heartburn and regurgitation was 17% (6–28%) and 28% (26–30%) respectively; in randomized trials, it was 32% (25–39%) and 28% (26–30%), respectively. In observational primary care and community-based studies, 45% (30–60%) of participants reported persistent GERD symptoms. Overall, persistent GERD symptoms despite PPI treatment were more likely in studies with a higher proportion of female participants [>60% vs. <50%, risk ratio (RR): 3.66; P < 0.001], but less likely in studies from Europe than in those from the USA (RR: 0.71; P < 0.001), and were associated with decreased psychological and physical well-being. Conclusions Persistent GERD symptoms despite PPI treatment are common in the primary care and community setting. Alternative approaches to management are required.
-
meta analysis Proton Pump Inhibitor or h2 receptor antagonist for helicobacter pylori eradication
Alimentary Pharmacology & Therapeutics, 2003Co-Authors: D Y Graham, Fadi Hammoud, Hala M T Elzimaity, Jong G Kim, Michael S Osato, Hashem B ElseragAbstract:Summary Aim : To compare H2-receptor antagonists and Proton Pump Inhibitors as adjuvants to triple therapy for Helicobacter pylori eradication. Methods : H. pylori-infected patients with peptic ulcer were randomized to receive either 300 mg nizatidine or 30 mg lansoprazole plus 1 g amoxicillin and 500 mg clarithromycin taken b.d. for 7 days. H. pylori eradication was assessed 4 weeks after therapy. Using meta-analytical techniques, we combined the results of this study with other randomized controlled comparisons of H2-receptor antagonists and Proton Pump Inhibitors as adjuvants to triple therapy. Results : One hundred and one patients were randomized. H. pylori eradication was 94% (47/50) [95% confidence interval (CI), 83–99%] (intention-to-treat) in the H2-receptor antagonist group vs. 86% (44/51) (95% CI, 74–94%) in the Proton Pump Inhibitor group (P = 0.3). There has been a total of 12 similar studies (1415 patients). The overall efficacy was similar in intention-to-treat analysis: 78% (549/701) with H2-receptor antagonists vs. 81% (575/714) with Proton Pump Inhibitors (odds ratio, 0.86; 95% CI, 0.66–1.12). A non-significant trend favouring H2-receptor antagonist (79% vs. 69%; odds ratio, 1.14; 95% CI, 0.76–1.71; P = 0.5) was seen in the comparison of clarithromycin-containing regimens. In contrast, in non-clarithromycin-containing trials, there was a slight, but significant, advantage with Proton Pump Inhibitors (85% vs. 78%; odds ratio, 0.64; 95% CI, 0.45–0.92; P = 0.02). Conclusion : Overall, Proton Pump Inhibitor andH2-receptor antagonist antisecretory agents appear to be similarly effective as adjuvants for H. pylori triple therapy. It is unlikely that the direct anti-H. pylori effect of Proton Pump Inhibitors is responsible for their ability to enhance anti-H. pylori therapy.
